Clinical trial
A Phase 1, Multicentre, 2-Part, Randomised, Parallel-arm, Placebo-controlled, Partially Double-blind Study to Evaluate the Safety and Target Engagement of EXL01 in the Maintenance of Steroid-induced Clinical Response or Remission in Participants With Mild to Moderate Crohn's Disease
NCT05542355 is registered in ClinicalTrials.gov with Exeliom Biosciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multicentre, 2-Part, Randomised, Parallel-arm, Placebo-controlled, Partially Double-blind Study to Evaluate the Safety and Target Engagement of EXL01 in the Maintenance of Steroid-induced Clinical Response or Remission in Participants With Mild to Moderate Crohn's Disease
- Lead sponsor
- Exeliom Biosciences
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- March 20, 2023
- Completion date
- October 2, 2024
- Enrollment
- 8 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.